Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | F11 | P03951 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | HMGCR | P04035 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8975481 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL8587293 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL22992331 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL10700645 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL13146114 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL7151003 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL10582500 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL22983992 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL22984008 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL12352428 | 1.00 | PTPN1 (0.57) | PTPN1USP2MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
| US-4313008-A | FROM A CHLORODEOXY-D-SACCHARIDE | TATE & LYLE LTD. (GB) | 1982-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | PTPN1 1751/4885USP2 2880/4885MEN1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.